Patent · US Active

HIV integrase inhibitors

US7763630B2 · kind B2 · utility

1Cited by

7References

17Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

B. Narasimhulu Naidu · Durham, US
Margaret E. Sorenson · Swedesburg, US
Manoj Patel · Berlin, US

Key dates

Filing date	Jun 3, 2008
Grant date	Jul 27, 2010
Priority date	—
Expiry date	Jun 3, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention encompasses a series pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.